Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 193

1.

Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.

Li Y, Bare LA, Bender RA, Sninsky JJ, Wilson LS, Devlin JJ, Waldman FM.

Mol Diagn Ther. 2015 Jun;19(3):169-77. doi: 10.1007/s40291-015-0140-9.

2.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24. Review.

PMID:
25443274
3.

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.

Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC.

Breast Cancer Res. 2013;15(5):R103.

4.

Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.

Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H, Ho A, Sanders H, Sferruzza A, Cheng SM, Nguyen D, Jones D, Waldman F.

J Mol Diagn. 2013 Nov;15(6):790-5. doi: 10.1016/j.jmoldx.2013.07.003. Epub 2013 Aug 28.

5.

Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ.

Shin SJ, Lal A, De Vries S, Suzuki J, Roy R, Hwang ES, Schnitt SJ, Waldman FM, Chen YY.

Hum Pathol. 2013 Oct;44(10):1998-2009. doi: 10.1016/j.humpath.2013.04.004. Epub 2013 Jun 25.

PMID:
23809857
6.

FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES.

Breast Cancer Res Treat. 2013 Jun;139(2):381-90. doi: 10.1007/s10549-013-2556-4. Epub 2013 May 28.

PMID:
23712790
7.

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?

Sadanandam A, Lal A, Benz SC, Eppenberger-Castori S, Scott G, Gray JW, Spellman P, Waldman F, Benz CC.

Breast Cancer Res Treat. 2012 Dec;136(3):693-703. doi: 10.1007/s10549-012-2290-3. Epub 2012 Oct 27.

8.

Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.

Moore LE, Jaeger E, Nickerson ML, Brennan P, De Vries S, Roy R, Toro J, Li H, Karami S, Lenz P, Zaridze D, Janout V, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Linehan WM, Merino M, Simko J, Pfeiffer R, Boffetta P, Hewitt S, Rothman N, Chow WH, Waldman FM.

Oncogenesis. 2012 Jun 25;1:e14. doi: 10.1038/oncsis.2012.14.

9.

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.

Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N.

PLoS Genet. 2011 Oct;7(10):e1002312. doi: 10.1371/journal.pgen.1002312. Epub 2011 Oct 13.

10.

Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA; Cancer and Leukemia Group B Pathology Committee.

J Clin Oncol. 2011 Jun 1;29(16):2282-90. doi: 10.1200/JCO.2010.33.2023. Epub 2011 Apr 25.

11.

Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ.

Hwang ES, Lal A, Chen YY, DeVries S, Swain R, Anderson J, Roy R, Waldman FM.

Hum Pathol. 2011 Oct;42(10):1467-75. doi: 10.1016/j.humpath.2011.01.002. Epub 2011 Apr 14.

PMID:
21496874
12.

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.

Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC.

Breast Cancer Res. 2010;12(5):R85. doi: 10.1186/bcr2753. Epub 2010 Oct 14.

13.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

14.

Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.

Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A.

Oncologist. 2010;15(4):390-404. doi: 10.1634/theoncologist.2009-0233. Epub 2010 Mar 29. Review.

15.

TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe.

SzymaƄska K, Moore LE, Rothman N, Chow WH, Waldman F, Jaeger E, Waterboer T, Foretova L, Navratilova M, Janout V, Kollarova H, Zaridze D, Matveev V, Mates D, Szeszenia-Dabrowska N, Holcatova I, Bencko V, Le Calvez-Kelm F, Villar S, Pawlita M, Boffetta P, Hainaut P, Brennan P.

Cancer Lett. 2010 Jul 1;293(1):92-8. doi: 10.1016/j.canlet.2009.11.024. Epub 2010 Feb 6.

PMID:
20137853
16.

Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.

Horvai AE, DeVries S, Roy R, O'Donnell RJ, Waldman F.

Mod Pathol. 2009 Nov;22(11):1477-88. doi: 10.1038/modpathol.2009.119. Epub 2009 Sep 4.

17.

Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.

Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, Fitzgibbons PL, Jacobs TW, MacGrogan G, Peterse H, Vincent-Salomon A, Tokuyasu T, Schnitt SJ, Waldman FM.

Am J Surg Pathol. 2009 Nov;33(11):1683-94. doi: 10.1097/PAS.0b013e3181b18a89.

18.

Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM, Hwang ES.

BMC Cancer. 2009 Aug 18;9:285. doi: 10.1186/1471-2407-9-285.

19.

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen S, Cote RJ.

J Clin Oncol. 2009 Aug 20;27(24):3929-37. doi: 10.1200/JCO.2008.18.5744. Epub 2009 Jul 20.

20.

Predictive models in external beam radiotherapy for clinically localized prostate cancer.

Roach M 3rd, Waldman F, Pollack A.

Cancer. 2009 Jul 1;115(13 Suppl):3112-20. doi: 10.1002/cncr.24348. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk